We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening

By LabMedica International staff writers
Posted on 12 Jun 2024

Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance imaging (mpMRI). More...

Now, a cost-effectiveness analysis has revealed that using biparametric magnetic resonance imaging (bpMRI) as an initial screening tool is less cost-effective than the traditional approach of first-line PSA testing followed by mpMRI. This conclusion held true even when assuming no cost for bpMRI, indicating that the financial savings do not compensate for the drawbacks of using the first-line MRI approach.

A team of researchers from Fred Hutchinson Cancer Center (Seattle, WA, USA), in collaboration with other institutions, developed a microsimulation model to compare the effectiveness and cost-efficiency of first-line bpMRI versus first-line PSA with reflex mpMRI for prostate cancer screening. The study showed that initiating screening with MRI significantly increased the incidence of false positives, unnecessary prostate biopsies, and overdiagnoses, without a corresponding significant decrease in prostate cancer mortality. The findings suggest that even free bpMRI screening does not offer economic or quality-of-life advantages over the conventional approach of PSA testing followed by mpMRI and, if necessary, MRI-guided prostate biopsy supplemented by transrectal ultrasonography–guided biopsy.

These results underline the importance of focusing screening strategies on minimizing false positives and overdiagnoses to enhance cost-effectiveness. High-quality cost-effectiveness analyses like this are vital for understanding how changes in medical practice impact the broader healthcare system. Moreover, incorporating economic data from such analyses could strengthen the development of guidance statements, as endorsed by the National Comprehensive Cancer Network. It is recommended that other organizations also consider integrating cost-effectiveness information into their guidelines to inform clinical decisions.

Related Links:
Fred Hutchinson Cancer Center


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.